Posted by Michael Wonder on 19 Nov 2020
NICE recommends another medicine for patients with multiple myeloma
18 November 2020 - Recommended for listing in the Cancer Drugs Fund.
Isatuximab, when used in combination with pomalidomide and dexamethasone, is recommended within the Cancer Drugs Fund as an option for the treatment of adults with relapsed and refractory multiple myeloma who have had lenalidomide and a proteasome inhibitor, and whose disease has progressed on their last treatment, only if:
- They have had 3 previous lines of treatment
- The conditions in the managed access agreement for isatuximab plus pomalidomide and dexamethasone are followed.
